Tuesday 28 June 2022
EU Joint Programme – Neurodegenerative Disease Research: Understanding the mechanisms of non-pharmacological interventions.
Deadlines:
Pre-proposals: March 1, 2022
Full proposals: June 28, 2022
Tuesday 28 June 2022
Deadlines:
Pre-proposals: March 1, 2022
Full proposals: June 28, 2022
Tuesday 28 June 2022
Financement : de 1 000 000 € à 3 000 000 € sur 6 ans maximum
Date limite de soumission des dossiers : 28 juin 2022
https://www.fondation-arc.org/aap2022-cancer-vieillissement
Thursday 30 June 2022
Exploratory awards: up to approximately $250,000
Proof-of-principle awards: up to $500,000
Validation awards: Award amounts will be based on stage and scope of research
Platforms : A variety of digital platforms such as portables, sensors, or software are encouraged. The proposed platform should have the potential to be easily deployed at scale. Passive approaches to data collection are encouraged.
Examples of digital approaches include, but are not limited to:
The following is out of scope for this RFP:
Note: The DxA is currently developing a speech and language biomarker consortium. Proposals outside this effort will not be considered at this time.
Symptom Domains : The RFP encourages digital biomarkers emerging from one or more of the symptom domains below. Proposed approaches will be evaluated based on the existing evidence around the biological link of the symptom domain to disease and how measuring the proposed symptom domain will improve current screening or monitoring methods in patients.
Symptom domains of interest include, but are not limited to:
Combinations of these or other symptom domains with a clear link to the disease are also encouraged.
Projects that succeed in the exploratory or proof-of-principle stage may be eligible for follow-on funding in the form of a validation award.
Thursday 30 June 2022
High-risk project for 2 years in basic research in ALS.
One or two grants of 200,000 Swiss francs will be given each year.
Deadline: 30 June 2022
https://www.radala-foundation.com/
Thursday 07 July 2022
To facilitate exchanges between clinical centres and/or laboratories involved in MS. Travel may be within, to, or from France.
Deadline: No deadline - throughout the year
Thursday 07 July 2022
La Fondation accompagne financièrement chaque projet sur une durée de 5 ans à hauteur de 2 millions d’euros, auxquels s’ajoutent la prise en charge des frais de gestion et la prime personnelle du chercheur.
Le premier appel à candidatures aura lieu en 2022.
Impulscience est ouvert aux chercheurs et chercheuses remplissant les conditions suivantes :
https://www.fondationbs.org/fr/sciences-de-la-vie/soutien-aux-chercheurs/impulscience
Friday 15 July 2022
On this page discover the funding opportunities of international foundations according to your activity topics
Below the exel version
Tuesday 19 July 2022
1-year awards with a maximum budget of $50,000 should be used to gather preliminary data that will support future applications to larger grant award programs.
Letter of Intent Due Date: May 17, 2022
Full Application Due Date (by invite only): July 19, 2022
https://www.als.org/research/funding-opportunities/seed-grants-2022
Thursday 21 July 2022
The publication of this call is the beginning of a journey connecting those who understand and can identify the needs with those who have the solution to ultimately deliver value to patients and citizens, as well as to our healthcare systems by and large.
Friday 22 July 2022
3 Deadlines:
-Letter of Intent: February 4, 2022
Invited Full Proposal: April 8, 2022
-Letter of Intent: May 20, 2022
Invited Full Proposal: July 22, 2022
-Letter of Intent: September 30, 2022
Invited Full Proposal: December 2, 2022
Award Amount: Up to $600,000 based on stage and scope of research.
Award Duration: One year with potential for follow-on funding.
https://www.alzdiscovery.org/research-and-grants/funding-opportunities/biomarkers
Monday 01 August 2022
We fund high risk or clinically based investigator-initiated projects through the External Awards Program. We also fund projects in high-priority applications of FUS through the Brain Program, Cancer Immunotherapy Program, and Veterinary Program, including both invited and investigator-initiated projects.
Brain program: It is the ultimate goal of the Foundation's Brain Program to see focused ultrasound become a standard of care for the treatment of a range of neurological disorders, including movement disorders, brain tumors, epilepsy and stroke.
The External Awards Program provides funding for investigator-initiated clinical, preclinical, and early-stage research projects through a competitive peer-reviewed application process.
The program has two tracks:
* The Pre-Clinical Track is geared primarily towards preclinical studies and research projects that target a particular clinical indication or organ. It is meant to fund research that could lead the way to a new reimbursable clinical application for image-guided FUS within five to seven years.
*The High-Risk Track is intended for early-stage, high-risk, proof-of-concept research that, if successful, could have a profound impact on the field of focused ultrasound and that could change the way many conditions are treated.
**Additionally, the External Awards Program accepts abstracts for Clinical Trial funding requests. The abstract form for Clinical Trials is linked in the Materials section below. Funding for clinical trials is not limited to $100,000 and one year.
Funding: one-year awards totaling approximately $100,000
The Pre-Clinical Track typically does not fund large capital purchases, cannot fund overhead or institutional expenses, and will not fund the development of new focused ultrasound equipment
Step 1: A one-page Research Abstract must be submitted at least two weeks prior to the program’s quarterly application deadlines (Feb. 1, May 1, Aug. 1, and Nov. 1).
Step 2: The Foundation will invite full Research Proposals from authors of approved Research Abstracts.
Funding decisions are returned to the applicant approximately three months after their application deadline.
https://fusfoundation.org/for-researchers/external-research-awards-program/apply-for-funding
https://fusfoundation.org/for-researchers/external-research-awards-program
Questions?
Please contact Matt Eames, PhD, Director of External Research, at meames@fusfoundation.org.
Thursday 08 September 2022
Cette mesure permettra de conserver les capacités humaines de R&D des entreprises françaises en difficulté suite la crise sanitaire, en contribuant au financement de salaire de personnels, et en facilitant l’emploi de jeunes diplômés à travers des collaborations entre des laboratoires Inserm et les entreprises.
L’Inserm dispose ainsi d’un financement lui permettant de préserver ou de créer plus de 200 emplois R&D dans les entreprises ou ses laboratoires dans le domaine de la Santé. Inserm Transfert, la filiale de l'Institut dédiée à la valorisation, sera le point de contact des entreprises qui souhaitent bénéficier des crédits du plan France relance pour créer, relancer ou renforcer, des partenariats de recherche avec des équipes Inserm.
Un élément indispensable : un programme de recherche collaboratif
Préservation de l’emploi R&D grâce à 2 mesures :
https://www.inserm-transfert.fr/industriels/plan-france-relance/
https://www.inserm.fr/nous-connaitre/inserm-et-plan-france-relance/
Thursday 15 September 2022
Exploratory awards: up to approximately $250,000
Proof-of-principle awards: up to $500,000
Validation awards: Award amounts will be based on stage and scope of research
Modalities: Blood and other peripheral markers, including saliva, urine, and ocular biomarkers are encouraged. The development of Cerebrospinal fluid (CSF) and neuroimaging biomarkers will not be considered for this program; however, we encourage the use of these modalities to validate proposed biomarkers.
Biomarker targets: Proposed approaches will be evaluated on biological plausibility linking the biomarker to disease pathophysiology. Examples of target areas of interest include, but are not limited to:
Other novel approaches that are supported by compelling evidence that demonstrate a rational biological connection to the disease process are encouraged.
Sample sharing program: Clinical validation of a biomarker requires well characterized samples across multiple cohorts. The Diagnostics accelerator has partnered with Janssen/Shionogi, Eisai and Roche pharmaceuticals to make available samples from their clinical trials to our researchers.
The peripheral RFP is open to all biomarker categories that will advance drug development for Alzheimer's and related dementias. The expected context of use, which defines a biomarker's intended use clinically as a diagnostic or in drug development, should be described in the application. These categories, as defined by the FDA, include diagnostic, monitoring, predictive, prognostic, pharmacodynamic/response, safety, and susceptibility/risk biomarkers. Additionally, the applicant should articulate where in the path to commercialization the study falls and what is the proposed plan forward.
Projects that succeed in the exploratory or proof-of-principle stage may be eligible for follow-on funding.
Friday 16 September 2022
![]() |
![]() |
![]() |
![]() |
More information : please download the document
Thursday 29 September 2022
NIH Funding Opportunities (Foreign Institutions are eligible to apply) / Financements NIH ouverts aux institutions non-US
Ensemble d'appels d'offres ouverts aux institutions non-US, on this page, a set of calls for proposals that are open to non-US institutions
Sunday 16 October 2022
The application deadlines are:
Awards are two years of funding totaling $200,000
https://grants.nih.gov/grants/guide/pa-files/PAS-19-393.html
Sunday 16 October 2022
The application deadlines are:
Awards are two years of funding totaling $200,000
https://grants.nih.gov/grants/guide/pa-files/PAS-19-392.html